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Introduction
============

As magnetic resonance imaging has become widely available and brain magnetic resonance imaging is increasingly being carried out in various clinical settings, clinicians often have to deal with the incidental discovery of white matter lesions, appearing as hyperintensities on T2 weighted images (fig 1[](#fig1){ref-type="fig"}). In the general population the prevalence of white matter hyperintensities ranges from 11-21% in adults aged around 64 to 94% at age 82.[@ref1] [@ref2] Pathological findings in regions of white matter hyperintensity include myelin pallor, tissue rarefaction associated with loss of myelin and axons, and mild gliosis.[@ref3] [@ref4] These lesions are located in the deep white matter, typically sparing subcortical U-fibres, and are often seen together with vessels affected by small vessel disease.[@ref5] The affected vessels are presumed to induce the lesions in deep white matter through chronic hypoperfusion of the white matter and disruption of the blood-brain barrier, leading to chronic leakage of plasma into the white matter.[@ref3] [@ref6] [@ref7] White matter hyperintensities are more common and extensive in patients with cardiovascular risk factors and symptomatic cerebrovascular disease.[@ref8] White matter hyperintensities can be measured quantitatively and non-invasively on large population samples and have been proposed as an intermediate marker, which could be used for the identification of new risk factors and potentially as a surrogate end point in clinical trials.[@ref9]

![**Fig 1** White matter hyperintensities on magnetic resonance imaging (axial fluid attenuated inversion recovery sequence) in two 80 year old patients: (left) minor white matter hyperintensities; (right) extensive white matter hyperintensities predominating in periventricular region. White matter lesions are considered present if hyperintense on T2 weighted, fluid attenuated inversion recovery, and proton density images, without prominent hypointensity on T1 weighted images](debs751180.f1_default){#fig1}

Several studies have assessed the relation between white matter hyperintensities and risk of stroke, dementia, and death, with partly conflicting results. We systematically reviewed and meta-analysed all published longitudinal studies that tested the association of white matter hyperintensities with risk of stroke, dementia, and death, both in the general population and in a hospital based setting.

Methods
=======

Using predefined search terms we identified references through searches of PubMed from 1966 to 23 November 2009 (see web extra methods 1). We also identified papers by reviewing the reference lists of relevant articles.

Study selection
---------------

Studies were limited to those in adults. We included only prospective studies with longitudinal data on the association of white matter hyperintensities with risk of stroke, dementia, cognitive decline, and death. We excluded studies if they evaluated white matter lesions only by computed tomography (because of the lower sensitivity of this method for measuring white matter lesions compared with magnetic resonance imaging[@ref10]); carried out magnetic resonance imaging at the end of follow-up instead of at baseline; or had a sample size of fewer than 50 patients. For studies with more than one publication describing results among overlapping groups of participants and with the same outcome measure, we included only the dataset with the longest follow-up. If the follow-up period was identical we included only the dataset with the largest number of patients (see web extra methods 2).

Data extraction
---------------

From the studies we extracted data on number of participants, general population versus high risk participants, mean age, duration of follow-up, characteristics of magnetic resonance imaging and definition of white matter hyperintensities, outcome definition (all strokes versus intracerebral haemorrhage or ischaemic stroke; all types of dementia versus Alzheimer's disease, vascular dementia, mixed vascular and Alzheimer's dementia; and neuropsychological measurements used to assess cognitive decline), and number of events that occurred during follow-up. For the measure of the association between white matter hyperintensities and the outcome we recorded, when available, hazard ratios, odds ratios, and adjustment variables when applicable. Both authors extracted the information from each study, resolving any disagreements by discussion.

Variable definition
-------------------

We defined studies as being in high risk populations if they were carried out in people selected for the presence of prevalent disease such as mild cognitive impairment, stroke, or other vascular events, or for the presence of a high risk factor profile. (See web extra tables 1-5 for the inclusion criteria for each study.) Stroke was defined as an acute onset focal neurological deficit of presumed vascular cause lasting at least 24 hours or interrupted by death within 24 hours. Web extra tables 1-5 show the number of events by stroke type (ischaemic versus haemorrhagic), when available. Unless specified differently (see web extra tables 1-5) we defined dementia according to the criteria of the *Diagnostic and Statistical Manual of Mental Disorders*, third or fourth editions[@ref11] [@ref12]; Alzheimer's disease based on the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association for definite, probable, or possible Alzheimer's disease[@ref13]; and vascular dementia according to the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences criteria.[@ref14] Cognitive decline was defined as worsening performance on repeated neuropsychological tests. In the absence of consensus on which neuropsychological test was the most appropriate, we did not apply restrictions on type of test used. We examined separately tests of global cognitive function and tests assessing performances in specific cognitive domains (see web extra tables 1-5 for types of test used in each study).

Web extra table 6 details study quality criteria, including loss to follow-up, surveillance carried out for the diagnosis of incident events, description of the definition used for these events, and event subtypes. We also report the availability of effect estimates and whether the analysis took into account time to event.

Statistical analyses
--------------------

Cochrane RevMan version 4·2 software ([www.cc-ims.net/RevMan/current.htm](www.cc-ims.net/RevMan/current.htm)) was used to carry out meta-analysis of the outcomes dementia, stroke, and death. Graphs were designed using the rmeta package in R (<http://cran.r-project.org/web/packages/rmeta/index.html>). We calculated pooled hazard ratios using the random effects inverse variance method. In a few studies only odds ratios were available despite the longitudinal design,[@ref15] [@ref16] [@ref17] therefore we considered the odds ratios as approximations of hazard ratios.[@ref18] Significant heterogeneity was defined by a P value \<0.05 or I^2^ \>50%. We carried out meta-analysis when at least three studies were available for the same outcome; we included only studies that used a categorical measure of white matter hyperintensities. When more than two categories were present we used the hazard ratio for the highest category compared with the lowest category. Studies for which the association of white matter hyperintensities with the outcome was studied solely in a continuous fashion (per unit increase or standard deviation increase in quantitative volume of white matter hyperintensities or semiquantitative grade for white matter hyperintensities) were not included in the meta-analysis. Indeed, white matter hyperintensities were measured on completely different scales in the various cohorts, using either automated quantitative volume measures or different types of visual semiquantitative non-linear volume measures. Although a sample size weighted meta-analysis could be done, this would not provide a pooled effect estimate. When both adjusted and unadjusted values were available for the hazard ratio, we included the value adjusted for vascular risk factors. For studies that measured deep white matter hyperintensities and periventricular hyperintensities separately and did not provide a global risk estimate for white matter hyperintensities, we meta-analysed the results for periventricular hyperintensities (see web extra methods 3). In a secondary analysis we reran the meta-analysis replacing the results for periventricular hyperintensities with those for deep white matter hyperintensities. All meta-analyses were done separately for population based studies and studies in a high risk population, and overall.

Results
=======

The initial search identified 958 articles, of which 53 met the inclusion criteria.[@ref15] [@ref16] [@ref17] [@ref19] [@ref20] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref59] [@ref60] [@ref61] [@ref62] [@ref63] [@ref64] [@ref65] [@ref66] [@ref67] [@ref68] This included 14 studies for stroke,[@ref15] [@ref16] [@ref19] [@ref20] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30] 20 for dementia,[@ref29] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] 21 for cognitive decline,[@ref17] [@ref22] [@ref23] [@ref29] [@ref39] [@ref46] [@ref48] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref59] [@ref60] [@ref61] [@ref62] [@ref63] and 11 for mortality.[@ref15] [@ref16] [@ref23] [@ref25] [@ref28] [@ref29] [@ref64] [@ref65] [@ref66] [@ref67] [@ref68] Some studies contained data on more than one outcome. Because of an overlap with another larger study carried out in the same population on the same outcome, seven studies were excluded: two on stroke,[@ref27] [@ref28] three on dementia,[@ref43] [@ref44] [@ref45] two on cognitive decline,[@ref51] [@ref59] and one on mortality.[@ref28] Hence a total of 46 studies was included in this systematic review[@ref15] [@ref16] [@ref17] [@ref19] [@ref20] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref52] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref60] [@ref61] [@ref62] [@ref63] [@ref64] [@ref65] [@ref66] [@ref67] [@ref68]; 12 for stroke,[@ref15] [@ref16] [@ref19] [@ref20] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref29] [@ref30] 17 for dementia,[@ref17] [@ref29] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref47] [@ref48] [@ref49] 19 for cognitive decline,[@ref17] [@ref22] [@ref23] [@ref29] [@ref39] [@ref46] [@ref48] [@ref50] [@ref52] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref60] [@ref61] [@ref62] [@ref63] and 10 for mortality.[@ref15] [@ref16] [@ref23] [@ref25] [@ref29] [@ref64] [@ref65] [@ref66] [@ref67] [@ref68]

White matter hyperintensities and incident stroke
-------------------------------------------------

### Incident stroke overall

Six population based studies[@ref15] [@ref19] [@ref20] [@ref21] [@ref29] [@ref30] and six studies in high risk populations[@ref16] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] examined the relation between white matter hyperintensities and incident stroke (see web extra table 1). All six population based studies could be included in the meta-analysis (fig 2[](#fig2){ref-type="fig"}), which showed a significant association of white matter hyperintensities with risk of stroke (hazard ratio 3.1, 95% confidence interval 2.3 to 4.1, P\<0.001). Three studies done in high risk populations could be included in the meta-analysis (fig 2), showing a significant association of white matter hyperintensities with the risk of stroke (7.4, 2.4 to 22.9, P=0.001).[@ref16] [@ref24] [@ref26] Three studies in high risk populations could not be included in the meta-analysis, two because white matter hyperintensities were studied continuously only,[@ref23] [@ref25] and a third because only intracerebral haemorrhage was studied as an outcome (see web extra table 1).[@ref22] All three found a significant association of white matter hyperintensities with incident stroke.

![**Fig 2** Inverse variance meta-analysis of studies testing association of white matter hyperintensities with incident stroke](debs751180.f2_default){#fig2}

The meta-analysis combining the data from population based and high risk populations yielded a significant association of white matter hyperintensities with incident stroke (3.5, 2.5 to 4.9, P\<0.001; see web extra fig 2).

### Incident stroke types

Few data existed on the association of white matter hyperintensities with specific stroke types (intracerebral haemorrhage, ischaemic stroke). One community based study[@ref21] found a significant association of white matter hyperintensities with incident ischaemic stroke; another study did not observe any association of white matter hyperintensities with recurrent intracerebral haemorrhage in patients with lobar haemorrhage (see web extra table 1).[@ref22]

### Progression of white matter hyperintensities and incident stroke

Only one study assessed the relation between progression of white matter hyperintensities and incident stroke, in 89 patients with a history of lacunar stroke, headache, or dizziness: a significantly increased risk of stroke was observed in patients with progression of white matter hyperintensities after 4.3 years compared with those with no progression.[@ref16]

White matter hyperintensities and incident dementia
---------------------------------------------------

### Incident dementia overall

Three population based studies[@ref29] [@ref31] [@ref32] and 11 studies in high risk populations[@ref17] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref47] [@ref48] examined the relation between white matter hyperintensities and incident dementia overall (see web extra table 2). Meta-analysing the three population based studies yielded a significant association of white matter hyperintensities with the occurrence of all types of dementia (2.9, 1.3 to 6.3, P=0.008; fig 3[](#fig3){ref-type="fig"}).[@ref29] [@ref31] [@ref32] Six of the 11 studies done in high risk populations could be included in the meta-analysis,[@ref17] [@ref37] [@ref39] [@ref41] [@ref47] [@ref48] yielding no significant association of white matter hyperintensities with incident dementia (1.4, 0.9 to 2.3, P=0.14). Four of these six studies included patients with mild cognitive impairment[@ref37] [@ref39] [@ref41] [@ref47]: meta-analysing these separately also did not yield any significant association (1.1, 0.8 to 1.6, P=0.46; see web extra fig 2). Five studies in high risk populations could not be included in the meta-analysis, three because white matter hyperintensities were studied continuously only,[@ref35] [@ref36] [@ref40] and two because the authors reported the absence of association without indicating numbers (see web extra table 2).[@ref34] [@ref38] None of them identified a significant association of white matter hyperintensities with incident dementia. Not all quality criteria were satisfied for several of the studies (see web extra table 6).[@ref34] [@ref37] [@ref38] [@ref48]

![**Fig 3** Inverse variance meta-analysis of studies testing association of white matter hyperintensities with incident dementia](debs751180.f3_default){#fig3}

When combining data from population based studies and high risk populations the risk of dementia associated with white matter hyperintensities was increased overall (1.9, 1.3 to 2.8, P=0.002; fig 3, also see web extra fig 3).

### Incident subtypes of dementia

Three population based studies[@ref31] [@ref32] [@ref33] and three studies in high risk populations[@ref41] [@ref42] [@ref49] investigated the relation between white matter hyperintensities and incident Alzheimer's disease (see web extra table 2). Only one population based study[@ref31] and two studies in high risk populations[@ref41] [@ref49] fulfilled our predefined criteria for meta-analysis. Meta-analysis of these yielded a significant association of white matter hyperintensities with the risk of Alzheimer's disease (see web extra fig 4).

Two population based studies[@ref31] [@ref33] and one study in a high risk population[@ref41] tested the relation between white matter hyperintensities and incident vascular dementia (see web extra table 2). We did not carry out a meta-analysis as only two studies fulfilled our predefined criteria for meta-analysis,[@ref31] [@ref41] but all three studies found a significant association of white matter hyperintensities with incident vascular dementia (see web extra table 2).

### Progression of white matter hyperintensities and incident dementia

One study observed that increasing volume of white matter hyperintensities during a two year follow-up was associated with incident dementia in depressed patients.[@ref38] Another study, in people with white matter hyperintensities of varying degree and mild neurological problems, found that increasing degrees of progression of white matter hyperintensities over a three year period were associated with a higher rate of conversion to dementia.[@ref48]

White matter hyperintensities and cognitive decline
---------------------------------------------------

### Global cognitive decline

Five population based studies assessed the relation between volume of white matter hyperintensities and global cognitive decline (see web extra table 3).[@ref29] [@ref39] [@ref50] [@ref53] [@ref63] Three studies observed that white matter hyperintensities were associated with an increased risk of low global cognitive test scores,[@ref50] conversion to mild cognitive impairment, or persistent cognitive impairment at the end of follow-up.[@ref39] [@ref63] In one study, white matter hyperintensities were associated with an increased risk of incident amnestic mild cognitive impairment in participants aged over 60,[@ref29] but did not predict incident mild cognitive impairment overall. Two studies found that increasing periventricular hyperintensities only predicted a higher rate of annual decline in mini-mental state examination scores,[@ref53] or of conversion to persistent cognitive impairment.[@ref63]

Eight studies carried out in high risk populations examined the relation of white matter hyperintensities with global cognitive decline (see web extra table 3).[@ref17] [@ref22] [@ref23] [@ref46] [@ref48] [@ref54] [@ref55] [@ref58] Five of them found that increasing baseline volume of white matter hyperintensities was associated with a more noticeable decline in global cognitive function.[@ref23] [@ref46] [@ref48] [@ref55] [@ref58] The other three studies observed no association.[@ref17] [@ref22] [@ref54]

### Decline in domain specific cognitive functions

Two population based studies evaluated the relation of volume of white matter hyperintensities with decline in domain specific cognitive functions[@ref52] [@ref53]: one found a significant association of periventricular hyperintensities (but not deep white matter hyperintensities) with decline in processing speed and executive function,[@ref53] whereas the other study observed no association of baseline burden of white matter hyperintensities with decline in any cognitive domain.[@ref52]

Four studies in high risk populations assessed the relation between white matter hyperintensities and decline in specific cognitive domains[@ref48] [@ref56] [@ref57] [@ref58]: all found an association of baseline white matter hyperintensities with more rapid change in executive function or processing speed. In two of these studies the association was assessed separately for periventricular hyperintensities and deep white matter hyperintensities and was significant for periventricular hyperintensities only.[@ref57] [@ref58]

### Progression of white matter hyperintensities and global cognitive decline

Two population based studies examined the relation of progression of white matter hyperintensities with decline in global cognitive functions (see web extra table 4).[@ref60] [@ref62] Both found that increasing progression of white matter hyperintensities was associated with a greater deterioration in global cognitive score; in one study this association was significant for periventricular hyperintensities only.[@ref62]

### Progression of white matter hyperintensities and decline in domain specific cognitive functions

Four population based studies tested the association of progression of white matter hyperintensities with decline in domain specific cognitive scores (see web extra table 4).[@ref52] [@ref60] [@ref61] [@ref62] One study observed a significant association of progression of white matter hyperintensities with decline in memory performance, conceptualisation, and visuopractical skills.[@ref52] The three other studies found an association of progression of white matter hyperintensities with a faster decline of executive functions or processing speed.[@ref60] [@ref61] [@ref62] In one study this association was significant for periventricular hyperintensities only.[@ref62]

Two studies tested the association of progression of white matter hyperintensities with decline in domain specific cognitive scores in high risk populations.(see web extra table 4).[@ref56] [@ref57] One study, in patients with vascular risk and no pre-existing cognitive impairment, found an association of progression in volume of periventricular hyperintensities with decline in executive function.[@ref57] The other study, in patients attending memory clinics who were already cognitively impaired, found no association of progression of white matter hyperintensities with memory or executive function.[@ref56]

White matter hyperintensities and mortality
-------------------------------------------

Four population based studies[@ref15] [@ref29] [@ref64] [@ref65] and six studies in high risk populations[@ref16] [@ref23] [@ref25] [@ref66] [@ref67] [@ref68] prospectively investigated the relation between white matter hyperintensities and mortality (see web extra table 5). All four population based studies could be included in the meta-analysis (fig 4[](#fig4){ref-type="fig"}), which showed a significant association of white matter hyperintensities with risk of death (2.3, 1.9 to 2.8, P\<0.001). Four studies done in high risk populations could also be meta-analysed (fig 4); this showed an association of white matter hyperintensities with mortality (1.6, 1.01 to 2.7, P=0.04). Two studies could not be included because white matter hyperintensities were studied continuously only,[@ref23] [@ref25] both found a significant association of white matter hyperintensities with mortality (see web extra table 5). When studies from both population based samples and high risk populations were pooled, white matter hyperintensities were associated with an increased risk of death during follow-up (2.0, 1.6 to 2.7, P\<0.001; fig 4, also see web extra fig 5).

![**Fig 4** Inverse variance meta-analysis of studies testing association of white matter hyperintensities with mortality](debs751180.f4_default){#fig4}

Discussion
==========

This systematic review of 46 studies, and meta-analysis, provides strong evidence that white matter hyperintensities are an important indicator of future risk of disease, being associated with an increased risk of stroke, cognitive decline (especially in the executive function and processing speed domains), dementia, and death.

Incident stroke
---------------

White matter hyperintensities were significantly associated with an increased risk of stroke, both in the general population and in high risk populations with a history of stroke or vascular disease. It could be hypothesised that this association merely reflects the relation of vascular risk factors with stroke. Indeed, age and hypertension are the main predictors of white matter hyperintensities,[@ref69] [@ref70] and other vascular risk factors such as smoking, diabetes, and history of vascular disease were also shown to be associated with lesions in white matter.[@ref71] In all studies, however, the association of white matter hyperintensities with stroke remained significant after adjustment for vascular risk factors. Although some residual confounding may exist, this suggests that white matter hyperintensities reflect either the overall effect of uncontrolled vascular risk factors better than the mere presence or absence of each individual factor or that other, yet unknown, factors play a role in the association of white matter hyperintensities with stroke.

Incident dementia and cognitive decline
---------------------------------------

White matter hyperintensities were associated with an increased risk of dementia in the general population, but not in studies on high risk populations (mainly with mild cognitive impairment or a history of stroke). When subtypes of dementia were assessed, the three studies that investigated the relation of white matter hyperintensities with incident vascular dementia found a significant association, both in the general population and in patients with mild cognitive impairment.[@ref31] [@ref33] [@ref41] Conversely, although the meta-analysis testing the relation of white matter hyperintensities with incident Alzheimer's disease yielded an overall significant association, this association was driven by the large population based study,[@ref31] whereas the two smaller studies on patients with mild cognitive impairment did not identify any association.[@ref41] [@ref49] Finally, our systematic review suggests that, in most studies looking at the association of white matter hyperintensities with decline in cognitive performance, white matter hyperintensities were associated with a faster decline in global cognitive performance as well as in executive function and processing speed. This was true both in the general population and in high risk patients with mild cognitive impairment, memory problem, or cerebrovascular disease.

Various potential mechanisms could account for the association of white matter hyperintensities with dementia. Firstly, subcortical neural networks could be damaged directly. Consistent with this hypothesis is the predominant association with decline in executive functions (believed to depend on cortical-subcortical circuits passing through the white matter), which could be disrupted by damage to white matter.[@ref56] [@ref72] Secondly, white matter hyperintensities could interact with pathological changes related to Alzheimer's disease and thereby accelerate their clinical expression, or vice versa.[@ref73] Thirdly, white matter hyperintensities could be a confounder reflecting the association of vascular risk factors[@ref74] or of concomitant ischaemic damage to the cortex with dementia. Several studies have adjusted for vascular risk factors, for prevalent or incident stroke, or for concomitant magnetic resonance imaging defined brain infarcts, and found similar results,[@ref29] [@ref31] [@ref32] suggesting that vascular risk factors are unlikely to be a major mechanism, although undetected cortical microinfarcts cannot be excluded.[@ref75] Finally, reverse causation through amyloid angiopathy or wallerian degeneration as a result of cortical atrophy has been hypothesised.[@ref76] [@ref77] However, data from the Austrian Stroke Prevention Study suggest that progression of lesions in white matter precedes loss in parenchymal volume in elderly people without dementia, implying that this reverse causation is unlikely to play a predominant role.[@ref52]

The finding that white matter hyperintensities were associated with an increased risk of dementia and Alzheimer's disease mainly in healthy populations and not in high risk patients who are already cognitively impaired, needs to be interpreted cautiously. Studies in high risk populations were carried out in small samples and had several methodological flaws. If this lesser association in higher risk and cognitively impaired populations is confirmed, however, it could suggest that once the neurodegenerative lesions become clinically evident, the effect of white matter lesions may be less important.[@ref78] As has been suggested by others, the presence of white matter hyperintensities may increase the risk that an individual will develop mild cognitive impairment or have declining performances on cognitive tests but may not be enough to facilitate progression from mild cognitive impairment to dementia, the latter being overwhelmingly driven by neurodegenerative lesions.[@ref36] [@ref41] [@ref47] An exception could be the rare cases of pure vascular dementia, where diffuse white matter hyperintensities could be important also at later stages of cognitive decline and conversion.[@ref41]

Mortality
---------

White matter hyperintensities were significantly associated with an increased risk of death both in the general population and in high risk populations with a history of stroke, depression, or minor neurological symptoms. This association could be mediated by an increased risk of stroke and dementia. However, both in the Rotterdam and the Framingham Offspring Study the association of white matter hyperintensities with mortality did not disappear after accounting for incident dementia or stroke.[@ref29] [@ref65] The association was more noticeable for cardiovascular mortality,[@ref29] [@ref65] [@ref67] which could reflect that white matter hyperintensities are a surrogate for an important burden of vascular risk factors and a marker of diffuse vascular damage involving not only the arteries supplying the brain but also peripheral and coronary arteries.[@ref24] [@ref79]

Effect of progression of white matter hyperintensities
------------------------------------------------------

Only three studies have assessed the impact of progression of white matter hyperintensities on incident stroke and dementia, suggesting a significant association of increasing progression of white matter hyperintensities with these outcomes.[@ref16] [@ref38] [@ref48] Progression of white matter hyperintensities has been more widely studied in association with cognitive decline, with increasing progression predicting a more rapid decline in global cognitive performance and executive function.[@ref52] [@ref56] [@ref57] [@ref60] [@ref61] [@ref62]

Limitations of the review
-------------------------

Although we corrected for statistical heterogeneity in the meta-analyses, the measurement and analysis of white matter hyperintensities varied substantially (see web extra tables 1-5). One important source of heterogeneity was the automated quantitative versus visual semiquantitative measurement of white matter hyperintensity volume, although visual semiquantitative scales were shown to correlate well with volumetric measures.[@ref80] Furthermore, total intracranial volume was unequally included in the analyses to account for differences in head size, and not all studies explicitly distinguished white matter hyperintensities from lacunar infarcts. Consensus recommendations on the measurement of white matter hyperintensities and their progression, as have been published for instance for carotid intima-media thickness,[@ref81] would be useful to improve the comparability of future studies. Another limitation is that some studies could not be included in the meta-analysis because white matter hyperintensity was studied only as a continuous variable using different scales. All the results, including those that were not incorporated in the meta-analysis, are available in web extra tables 1-5. The pooled hazard ratios for dichotomous measures of burden of white matter hyperintensities also need to be interpreted with caution, given the heterogeneous definitions of these measures across studies. They should therefore not be extrapolated to estimate the individual risk of stroke, dementia, or death in a patient with white matter hyperintensities on magnetic resonance imaging. To be as comprehensive as possible in this review we included studies using different tests or criteria for the diagnosis of cognitive decline and dementia, which is an additional source of heterogeneity. Finally, given the strong association of vascular risk factors both with burden of white matter hyperintensities and with the clinical outcomes we studied, it would be interesting to assess the modifying effect of these risk factors on the associations we reported. This was not feasible in the present paper, however, as the nature and definition of vascular risk factors included in the analyses varied substantially across studies.

Implications of the review
--------------------------

The findings of this review have several implications. For the clinician, they emphasise the clinical importance of white matter hyperintensities, even when these are found as incidental findings on brain imaging. In such cases doctors might consider detailed screening for risk factors for stroke and dementia, even though the benefit of doing so is not formally proved. Although data showing that treatment of risk factors reduces the progression of white matter hyperintensities are limited, more aggressive antihypertensive treatment was associated with reduced progression in patients after stroke, as well as with a reduction in stroke itself.[@ref82]

In terms of research, white matter hyperintensities could constitute a potentially useful intermediate marker for the identification of new risk factors for stroke and dementia. Indeed, besides being strongly associated with the risk of stroke and dementia, white matter hyperintensities can be quantified reliably and non-invasively on large samples and can be measured as a continuous trait, thus providing increased statistical power to detect an association. White matter hyperintensities could prove particularly interesting for the identification of novel genetic risk factors, as their heritability was shown to be as high as 55-73%.[@ref83] [@ref84]

White matter hyperintensities may also have a role as a surrogate marker to assess treatment efficacy. Despite the importance of treatment, few have been shown to be specifically effective in the small vessel disease subtype of stroke. Treatment trials for small vessel disease face major challenges, including relatively slow progression of the disease necessitating large patient populations.[@ref85] Neuropathological studies have shown that white matter hyperintensities usually represent pathological small vessel disease,[@ref3] [@ref5] therefore white matter lesions may be useful to screen treatments before evaluation in much larger clinical studies, using stroke and dementia as clinical end points.[@ref9] The European Task Force on Age-Related White Matter Changes estimated that 195 people with confluent lesions would be required per treatment arm to show a 20% reduction in the rate of disease progression over three years.[@ref9] Criteria have been proposed for the use of imaging markers as surrogate markers for treatment trials.[@ref86] The first criterion was that the marker must be able to predict the natural course of the disease and should correlate with relevant clinical features in both cross sectional and longitudinal studies. Our meta-analysis provides strong evidence that this applies to white matter hyperintensities. A second criterion was that therapeutic interventions can delay progression of surrogate markers and that this correlates with reduced occurrence of clinical end points. Support for this is available from the magnetic resonance imaging substudy of the Perindopril Protection against Recurrent Stroke Study, which revealed a less noticeable progression of white matter hyperintensities with aggressive antihypertensive treatment, particularly in the subgroup of patients with a higher volume of white matter hyperintensities at study entry[@ref82]; an effect on clinical end points (stroke and cognitive decline) was also found in the main study.[@ref87]

Conclusions
-----------

In conclusion, our systematic review and meta-analysis provides strong evidence that white matter hyperintensities predict the risk of stroke, dementia, and mortality. This emphasises that white matter hyperintensities indicate increased cerebrovascular risk when identified clinically as part of diagnostic investigations and supports their use as an intermediate marker in a research setting. Further studies assessing the impact of progression of white matter hyperintensities on stroke and dementia are needed to help design therapeutic trials incorporating progression of white matter hyperintensities as an intermediate end point.

### What is already known on this topic

1.  Studies have assessed the relation between white matter lesions and risk of stroke, cognitive decline, dementia, and mortality

2.  The results are, however, partly conflicting

3.  Heterogeneity of study designs, imaging types, setting, sample size, and follow-up makes the interpretation of published data difficult

### What this study adds

1.  White matter hyperintensities are associated with an increased risk of stroke, dementia, and death

2.  For stroke and death the association was present in both community based and high risk populations, whereas for dementia the association was significant for community based patients only
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